Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Thomas P. Hank

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8087-2295; OpenAlex author ID A5008433221. Sources: OpenAlex.

Their work

Papers
53 (first author 8, last author 7)
Trials
0
Grants
0
Labs led
2
Collaborators
179
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 6 papers · 2021: 8 papers · 2022: 8 papers · 2023: 5 papers · 2024: 2 papers · 2025: 5 papers · 2026: 12 papers

Papers 50 of 53

  1. [S3 guidelines on exocrine pancreatic cancer 2024 : Consequences for the surgical practice]. Co-author DOI 10.1007/s00104-026-02561-7↗
  2. Impact of sarcopenia and myosteatosis on early and long-term survival after surgical resection of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2026.04.007↗
  3. Response to: "Impact of sarcopenia and myosteatosis on early and long-term survival after surgical resection of pancreatic ductal adenocarcinoma". First author DOI 10.1016/j.pan.2026.10.002↗
  4. Dual mTORC1/2 and Scd1 inhibition uncovers a therapeutic vulnerability in pancreatic cancer. Co-author DOI 10.1038/s41388-026-04026-x↗
  5. New implications from long-term outcomes of perioperative therapy in resectable pancreatic cancer. Co-author DOI 10.1038/s41416-025-03295-9↗
  6. Preoperative Surgical or Endoscopic Bile Duct Drainage in Pancreatic Cancer. First author DOI 10.1097/sla.0000000000006407↗
  7. Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) After Pancreatic Cancer Resection: A Retrospective Cohort Study. Co-author DOI 10.1245/s10434-025-18698-4↗
  8. ASO Visual Abstract: Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) after Pancreatic Cancer Resection: A Retrospec… Co-author DOI 10.1245/s10434-025-18864-8↗
  9. Optimal Time Between Completion of Preoperative Chemotherapy and Surgery for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-19264-2↗
  10. Neoadjuvant therapy for left-sided resectable pancreatic ductal adenocarcinoma: evidence-based shift or premature extrapolation? Co-author DOI 10.21037/hbsn-2025-587↗
  11. Tumor Location and Preoperative Biliary Stenting Shape Gut Microbiome Diversity in Pancreatic Cancer. Last author DOI 10.3390/cancers18162617↗
  12. Preoperative biliary stenting is associated with functional dysbiosis and impaired bile acid metabolism in pancreatic cancer - Impact of preoperative biliary s… Last author DOI 10.64898/2026.05.19.719953↗
  13. High prevalence of pancreatic steatosis in pancreatic cancer patients: A meta-analysis and systematic review. Co-author DOI 10.1016/j.pan.2024.11.010↗
  14. Prognostic factors for very early recurrence after neoadjuvant treatment and curative resection in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.surg.2025.109647↗
  15. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Last author DOI 10.1097/sla.0000000000006650↗
  16. Neoadjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006687↗
  17. Collagen XVII Promotes Pancreatic Ductal Adenocarcinoma Tumor Growth through Regulation of PIK3R5. Co-author DOI 10.1158/2767-9764.crc-24-0392↗
  18. Prognostic impact of resection margin status on survival after neoadjuvant treatment for pancreatic cancer: systematic review and meta-analysis. First author DOI 10.1097/js9.0000000000000792↗
  19. The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment. Last author DOI 10.1097/sla.0000000000005874↗
  20. Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer. Last author DOI 10.1016/j.ejca.2023.113293↗
  21. Presence of low-grade IPMN at the pancreatic transection margin does not have prognostic significance after resection of IPMN-associated pancreatic adenocarcin… Co-author DOI 10.1016/j.ejso.2022.08.003↗
  22. Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus. Co-author DOI 10.1016/j.esmoop.2023.102067↗
  23. Oncological Outcome of Conversion Surgery After Preoperative Chemotherapy for Metastatic Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005481↗
  24. Resected Early-Onset Pancreatic Cancer: Practices and Outcomes in an International Dual-Center Study. Co-author DOI 10.1245/s10434-022-12901-6↗
  25. Refined prognostic staging for resected pancreatic cancer by modified stage grouping and addition of tumour grade. Co-author DOI 10.1016/j.ejso.2021.07.020↗
  26. IPMN-associated pancreatic cancer: Survival, prognostic staging and impact of adjuvant chemotherapy. Co-author DOI 10.1016/j.ejso.2021.12.009↗
  27. Development and validation of the Massachusetts General Hospital/Memorial Sloan Kettering nomogram to predict overall survival of resected patients with pancre… Co-author DOI 10.1016/j.surg.2022.05.024↗
  28. Imaging features of intraductal tubulopapillary neoplasm of the pancreas and its differentiation from conventional pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41598-022-19517-6↗
  29. Prognostic relevance of the revised R status definition in pancreatic cancer: meta-analysis. Co-author DOI 10.1093/bjsopen/zrac010↗
  30. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: Th… Co-author DOI 10.1097/sla.0000000000004143↗
  31. Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma: Who Beats the Odds? Co-author DOI 10.1097/sla.0000000000004147↗
  32. A Pretreatment Prognostic Score to Stratify Survival in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000004845↗
  33. Neoadjuvant Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2020.6273↗
  34. Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer. First author DOI 10.1002/bjs.12003↗
  35. Prospective trial to evaluate the prognostic value of different nutritional assessment scores for survival in pancreatic ductal adenocarcinoma (NURIMAS Pancrea… Co-author DOI 10.1002/jcsm.12796↗
  36. [Surgery for periampullary pancreatic cancer]. Co-author DOI 10.1007/s00104-021-01462-1↗
  37. Clinical presentation and prognosis of adenosquamous carcinoma of the pancreas - Matched-pair analysis with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2021.02.011↗
  38. Adaptation of pancreatic cancer cells to nutrient deprivation is reversible and requires glutamine synthetase stabilization by mTORC1. Co-author DOI 10.1073/pnas.2003014118↗
  39. Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003270↗
  40. Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-20-1039↗
  41. Prognostic Value of Pancreatic Fistula in Resected Patients With Pancreatic Cancer With Neoadjuvant Therapy-Reply. Co-author DOI 10.1001/jamasurg.2019.5091↗
  42. Diabetes mellitus is associated with unfavorable pathologic features, increased postoperative mortality, and worse long-term survival in resected pancreatic ca… Co-author DOI 10.1016/j.pan.2019.10.007↗
  43. Primary and Metastatic Pancreatic Cancer Cells Exhibit Differential Migratory Potentials. First author DOI 10.1097/mpa.0000000000001459↗
  44. Microscopic size measurements in post-neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes. Co-author DOI 10.1111/his.14067↗
  45. Neoplastic-Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-20-0439↗
  46. Main Pancreatic Duct to Parenchymal Thickness Ratio at Preoperative Imaging is Associated with Overall Survival in Upfront Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-08040-0↗
  47. Local radicality and survival outcome of pancreatic cancer surgery. First author DOI 10.1002/ags3.12273↗
  48. Conversion Surgery for Advanced Pancreatic Cancer. Co-author DOI 10.3390/jcm8111945↗
  49. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail. Co-author DOI 10.1002/bjs.10842↗
  50. Pancreatic Cancer Surgery: The New R-status Counts. First author DOI 10.1097/sla.0000000000001731↗

Closest collaborators

The 25 strongest of 179 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Oliver Strobel · 28 shared papers, 2015–2026 · strength 4.39
  2. Thilo Hackert · 24 shared papers, 2015–2026 · strength 3.89
  3. Markus Wolfgang Büchler · 23 shared papers, 2015–2026 · strength 3.64
  4. Martin Loos · 11 shared papers, 2025–2026 · strength 2.95
  5. Carl-Stephan Leonhardt · 12 shared papers, 2022–2026 · strength 2.41
  6. Keith D. Lillemoe · 13 shared papers, 2020–2025 · strength 1.75
  7. Andrew Louis Warshaw · 11 shared papers, 2020–2025 · strength 1.52
  8. Mohammed Al‐Saeedi · 6 shared papers, 2022–2026 · strength 1.47
  9. Christoph W. Michalski · 6 shared papers, 2025–2026 · strength 1.46
  10. Ulla Klaiber · 9 shared papers, 2021–2024 · strength 1.44
  11. Carlos F. Fernandez-del Castillo · 10 shared papers, 2020–2025 · strength 1.42
  12. Ingmar Florin Rompen · 6 shared papers, 2025–2026 · strength 1.37
  13. Motaz Qadan · 9 shared papers, 2020–2025 · strength 1.25
  14. Jörg Kaiser · 8 shared papers, 2018–2025 · strength 1.13
  15. Cristina Rosa Ferrone · 8 shared papers, 2020–2024 · strength 0.98
  16. John P. Neoptolemos · 4 shared papers, 2021–2026 · strength 0.96
  17. Klaus Sahora · 5 shared papers, 2021–2025 · strength 0.96
  18. Martin Schindl · 5 shared papers, 2021–2025 · strength 0.96
  19. Max Heckler · 5 shared papers, 2021–2026 · strength 0.93
  20. Niels Siegel · 2 shared papers, 2026 · strength 0.91
  21. Marta Sandini · 6 shared papers, 2020–2025 · strength 0.83
  22. Christoph Springfeld · 4 shared papers, 2017–2026 · strength 0.80
  23. Marionna Cathomas · 3 shared papers, 2026 · strength 0.76
  24. Mari A. Mino-Kenudson · 6 shared papers, 2020–2025 · strength 0.72
  25. Franco Fortunato · 3 shared papers, 2026 · strength 0.69

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.